Biotech Briefing: FDA Events & Recent Clinical Trials Fuel Therapeutic Advancements That Continue to Drive the Pharma & Biotech Sectors

CORAL SPRINGS, Florida, July 13, 2015 /PRNewswire/ --

Biotech, Pharma & Healthcare stocks soared in 2014, and 2015 is shaping up to be another great year for stocks as forecasted by some industry analysts.  The Nasdaq Biotechnology Index ETF returned an impressive 33% last year, significantly outpacing the performance of the S&P 500.   Biotech & Pharma Companies in focus today from around the sector are:  Amarantus BioScience Holdings, Inc. (OTCQX: AMBS), Zogenix, Inc. (NASDAQ: ZGNX), Gilead Sciences, Inc. (NASDAQ: GILD), Pfizer Inc. (NYSE: PFE) and XOMA Corp  (NASDAQ: XOMA)

Amarantus BioScience Holdings, Inc. (OTC: AMBS), a biotechnology company focused on developing therapeutic and diagnostic products for diseases in the areas of neurology, psychiatry, ophthalmology and regenerative medicine, announced that it has received approval to commence trading on the OTCQX® Best Marketplace (OTCQX) at market open today, July 13, 2015, under existing ticker symbol, "AMBS."

Read the full AMBS Press Releases at http://www.financialnewsmedia.com/profiles/ambs.html

"We are very pleased to have achieved OTC Markets Group's requirements for its premier securities marketplace," said Gerald E. Commissiong, President and Chief Executive Officer of Amarantus. "Trading on the OTCQX is another step toward our goal of a near-term up-listing to a national stock exchange, and will improve the Company's ability to attract institutional investors from both inside and outside the United States. This latest corporate milestone should provide additional visibility within the investment community enabling us to build awareness more broadly and expand the current shareholder base in order to drive shareholder value." 

In other biotech and pharmaceutical company news and developments:  Zogenix, Inc. (NASDAQ: ZGNX), News - Zogenix Expands Senior Leadership Team to Further Drive Strategic Focus on CNS Disorders and Orphan Drug Development - The Company announced last week the appointments of Gail M. Farfel, Ph.D., as Executive Vice President and Chief Development Officer, and Thierry Darcis, M.D., M.B.A., as Executive Vice President and General Manager, Europe.  "The addition of two highly experienced product development and commercial leaders in the orphan CNS disease category further advances our core strategic focus on the Company's late-stage CNS product development pipeline," said Stephen Farr, Chief Executive Officer of Zogenix. "We are extremely pleased to have both Gail and Thierry join Zogenix at this exciting time in the Company's history.

Gilead Sciences, Inc. (NASDAQ: GILD) announced this month that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for an investigational, once-daily single tablet regimen that combines Gilead's emtricitabine 200 mg and tenofovir alafenamide (TAF) 25 mg with rilpivirine 25 mg (R/F/TAF) from Janssen Sciences Ireland UC, one of the Janssen Pharmaceutical Companies of Johnson & Johnson, for the treatment of HIV-1 infection in adult and pediatric patients 12 years of age and older. The data submitted in the NDA support the use of R/F/TAF among patients who are HIV treatment-naïve or who are virologically suppressed and want to replace their current antiretroviral treatment regimen.

Pfizer Inc. (NYSE: PFE) recently announced enrollment of the first patient in a Phase 2b clinical trial of its investigational Staphylococcus aureus (S. aureus) multi-antigen vaccine (PF-06290510) in adults undergoing elective spinal fusion surgery. The purpose of the study, named STRIVE (STaphylococcus aureus SuRgical Inpatient Vaccine Efficacy), is to evaluate the safety and efficacy of the vaccine to determine if it prevents postoperative invasive S. aureus infections in patients undergoing elective spinal surgery.

Shares of XOMA Corp  (NASDAQ: XOMA) finished Friday's regular trading session in the green, up 4.9% to $4.71 on heavy volume, following the release of an upbeat analyst note out of Piper Jaffray on Friday morning.  The firm said it expects Phase III data of its gevokizumab product to be released.  Berkeley, Calif.-based XOMA is engaged in the discovery and development of antibody-based therapeutics.  Piper analysts said they are confident in a positive read-out, and added that the risk/reward ratio is favorable.  Read the full article at http://www.thestreet.com/story/13215161/1/xoma-stock-closed-in-the-green-following-upbeat-piper-note.html?puc=yahoo&cm_ven=YAHOO

FinancialNewsMedia.com is leading provider of third party publishing & news dissemination services.  If you would like more information regarding our news coverage solutions, please visit http://www.financialnewsmedia.com for more details.  Get an edge on the market with our Premium News Alerts that are FREE for a limited time at http://www.financialnewsmedia.com/.  Follow us on Facebook:  http://www.facebook.com/financialnewsmedia and Twitter: http://twitter.com/FNMgroup. 

DISCLAIMER:  FN Media Group LLC (FNMG) is a third party publisher and news dissemination service provider, which disseminates electronic information through multiple online media channels.  FNMG is NOT affiliated in any manner with any company mentioned herein.  FNMG and its affiliated companies are a news dissemination solutions provider and are NOT a registered broker/dealer/analyst/adviser, holds no investment licenses and may NOT sell, offer to sell or offer to buy any security.  FNMG's market updates, news alerts and corporate profiles are NOT a solicitation or recommendation to buy, sell or hold securities.  The material in this release is intended to be strictly informational and is NEVER to be construed or interpreted as research material.  All readers are strongly urged to perform research and due diligence on their own and consult a licensed financial professional before considering any level of investing in stocks.  All material included herein is republished content and details which were previously disseminated by the companies mentioned in this release.  FNMG is not liable for any investment decisions by its readers or subscribers.  Investors are cautioned that they may lose all or a portion of their investment when investing in stocks.  For current services performed FNMG has been compensated one thousand nine hundred dollars for news coverage of the current press release issued by Amarantus BioScience Holdings, Inc. by the company.  FNMG HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE. 

This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company's annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and FNMG undertakes no obligation to update such statements.

Contact Information:
Company:  FN Media Group, LLC
Contact email:  [email protected]
U.S. Phone: +1(954)345-0611
URL: http://www.financialnewsmedia.com

SOURCE FN Media Group LLC